Comparison of Secukinumab 300 mg Combined With a Lifestyle Intervention to Secukinumab Alone for the Treatment of Moderate to Severe Psoriasis Patients With Concomitant Metabolic Syndrome

PHASE4CompletedINTERVENTIONAL
Enrollment

781

Participants

Timeline

Start Date

February 28, 2018

Primary Completion Date

November 30, 2021

Study Completion Date

June 3, 2022

Conditions
PsoriasisMetabolic Syndrome
Interventions
DRUG

Secukinumab

Secukinumab 300 mg s.c., which consisted of two injections with 150 mg prefilled syringes at weeks 0, 1, 2, 3, 4, 8, 12, 16, 20 and 24 (last injection was performed at week 24)

BEHAVIORAL

Life-style intervention

A structured program to guide weight loss and increased physical activity

Trial Locations (74)

10117

Novartis Investigative Site, Berlin

10783

Novartis Investigative Site, Berlin

10789

Novartis Investigative Site, Berlin

13055

Novartis Investigative Site, Berlin

13088

Novartis Investigative Site, Berlin

13125

Novartis Investigative Site, Berlin

13187

Novartis Investigative Site, Berlin

13353

Novartis Investigative Site, Berlin

13507

Novartis Investigative Site, Berlin

13597

Novartis Investigative Site, Berlin

14467

Novartis Investigative Site, Potsdam

14612

Novartis Investigative Site, Falkensee

17475

Novartis Investigative Site, Greifswald

22303

Novartis Investigative Site, Hamburg

22391

Novartis Investigative Site, Hamburg

24105

Novartis Investigative Site, Kiel

26133

Novartis Investigative Site, Oldenburg

30625

Novartis Investigative Site, Hanover

32584

Novartis Investigative Site, Löhne

32756

Novartis Investigative Site, Detmold

33647

Novartis Investigative Site, Bielefeld

37075

Novartis Investigative Site, Göttingen

38100

Novartis Investigative Site, Braunschweig

39104

Novartis Investigative Site, Magdeburg

39120

Novartis Investigative Site, Magdeburg

40212

Novartis Investigative Site, Düsseldorf

40225

Novartis Investigative Site, Düsseldorf

41061

Novartis Investigative Site, Mönchengladbach

42109

Novartis Investigative Site, Wuppertal

42349

Novartis Investigative Site, Wuppertal

42897

Novartis Investigative Site, Remscheid

44791

Novartis Investigative Site, Bochum

44793

Novartis Investigative Site, Bochum

46147

Novartis Investigative Site, Oberhausen

48149

Novartis Investigative Site, Münster

49074

Novartis Investigative Site, Osnabrück

49377

Novartis Investigative Site, Vechta

49477

Novartis Investigative Site, Ibbenbueren

49565

Novartis Investigative Site, Bramsche

49809

Novartis Investigative Site, Lingen

50937

Novartis Investigative Site, Cologne

53105

Novartis Investigative Site, Bonn

55131

Novartis Investigative Site, Mainz

55469

Novartis Investigative Site, Simmern

56242

Novartis Investigative Site, Selters

56626

Novartis Investigative Site, Andernach

58095

Novartis Investigative Site, Hagen

58515

Novartis Investigative Site, Lüdenscheid

59494

Novartis Investigative Site, Soest

60590

Novartis Investigative Site, Frankfurt

63450

Novartis Investigative Site, Hanau

63500

Novartis Investigative Site, Seligenstadt

64283

Novartis Investigative Site, Darmstadt

65812

Novartis Investigative Site, Bad Soden

70178

Novartis Investigative Site, Stuttgart

79098

Novartis Investigative Site, Freiburg im Breisgau

80377

Novartis Investigative Site, München

80469

Novartis Investigative Site, München

81377

Novartis Investigative Site, München

86179

Novartis Investigative Site, Augsburg

87700

Novartis Investigative Site, Memmingen

88045

Novartis Investigative Site, Friedrichshafen

89081

Novartis Investigative Site, Ulm

89129

Novartis Investigative Site, Langenau

91054

Novartis Investigative Site, Erlangen

91224

Novartis Investigative Site, Pommelsbrunn

01097

Novartis Investigative Site, Dresden

01307

Novartis Investigative Site, Dresden

07548

Novartis Investigative Site, Gera

06108

Novartis Investigative Site, Halle

04103

Novartis Investigative Site, Leipzig

04105

Novartis Investigative Site, Leipzig

08529

Novartis Investigative Site, Plauen

06484

Novartis Investigative Site, Quedlinburg

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY